Telegraph Hill Partners Announces Appointment of Paul D. Grossman as Venture Partner

Former Life Technologies’ Head of Strategy & Corporate Development Expands Firm’s Technology, Business Strategy and Operating Expertise
San Francisco, February 10, 2014—Telegraph Hill Partners (THP), a leading venture capital and growth equity firm dedicated exclusively to life science and healthcare investing, today announced the addition of Paul D. Grossman, Ph.D. to its investment team as a Venture Partner.

Dr. Grossman, a 32-year veteran of the life science industry, has extensive experience within the laboratory tools and instruments sector. Most recently, Dr. Grossman was Head of Global Strategy and Corporate Development at Life Technologies, Inc. In that role, he was responsible for spearheading the company’s corporate strategy, licensing, business development and acquisition activities. Dr. Grossman held the same position at Invitrogen Corporation prior to the merger with Applied Biosystems in 2008. Prior to joining Invitrogen, Dr. Grossman held a variety of leadership roles during his more than 25 years at Applied Biosystems, including research scientist, patent attorney, Vice President of Intellectual Property and Vice President of Strategy and Business Development. Dr. Grossman received bachelors and Ph.D. degrees in chemical engineering from the University of California, Berkeley, a master’s degree in chemical engineering from the University of Virginia, and a J.D. from Santa Clara University School of Law. He has authored numerous scientific publications and holds more than 20 U.S. patents.

“We are delighted to have Paul join our team. For over three decades Paul has been one of the leading innovators in the life science industry, initially as a scientist and later as a business strategist. Paul’s experience and insights will contribute to our investment decisions as we deploy our new fund, and will be a tremendous benefit to our portfolio companies,” said Matt Mackowski, Chairman of THP.

Dr. Grossman will be located in San Diego focused on developing new strategies, sourcing new opportunities and supporting the growth plans of existing THP portfolio companies.

About Telegraph Hill Partners

Telegraph Hill Partners, founded in 2001 and based in San Francisco and San Diego, CA, invests in commercial stage life science, medical technology and healthcare companies. THP manages $600M across three funds, and closed on THPIII with capital commitments of $310M in 2013.